Recombinant
RabMAb

Recombinant Anti-ASS1 antibody [EPR12398] (HRP) (ab209018)

Overview

  • Product name

    Anti-ASS1 antibody [EPR12398] (HRP)
    See all ASS1 primary antibodies
  • Description

    Rabbit monoclonal [EPR12398] to ASS1 (HRP)
  • Host species

    Rabbit
  • Conjugation

    HRP
  • Tested applications

    Suitable for: WB, IHC-Pmore details
  • Species reactivity

    Reacts with: Human
    Predicted to work with: Mouse, Rat
  • Immunogen

    Synthetic peptide within Human ASS1 aa 1-100. The exact sequence is proprietary.
    Database link: P00966

  • Positive control

    • WB: HeLa whole cell lysate (ab150035), Human Fetal Liver tissue lysate. IHC-P: FFPE normal human liver tissue sections.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab209018 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/5000. Detects a band of approximately 44 kDa (predicted molecular weight: 47 kDa).
IHC-P 1/50. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Target

  • Pathway

    Amino-acid biosynthesis; L-arginine biosynthesis; L-arginine from L-ornithine and carbamoyl phosphate: step 2/3.
    Nitrogen metabolism; urea cycle; (N(omega)-L-arginino)succinate from L-aspartate and L-citrulline: step 1/1.
  • Involvement in disease

    Defects in ASS1 are the cause of citrullinemia type 1 (CTLN1) [MIM:215700]. Citrullinemia belongs to the urea cycle disorders. It is an autosomal recessive disease characterized primarily by elevated serum and urine citrulline levels. Ammonia intoxication is another manifestation. CTLN1 usually manifests in the first few days of life. Affected infants appear normal at birth, but as ammonia builds up in the body they present symptoms such as lethargy, poor feeding, vomiting, seizures and loss of consciousness. Less commonly, a milder CTLN1 form can develop later in childhood or adulthood.
  • Sequence similarities

    Belongs to the argininosuccinate synthase family. Type 1 subfamily.
  • Information by UniProt
  • Database links

  • Alternative names

    • Argininosuccinate synthase 1 antibody
    • Argininosuccinate synthase antibody
    • Argininosuccinate synthetase 1 antibody
    • ASS antibody
    • Ass-1 antibody
    • ass1 antibody
    • ASSA antibody
    • ASSY_HUMAN antibody
    • Citrulline aspartate ligase antibody
    • Citrulline--aspartate ligase antibody
    • CTLN1 antibody
    see all

Images

  • Anti-ASS1 antibody [EPR12398] (HRP) (ab209018) at 1/5000 dilution + Liver (Human) Tissue Lysate - fetal normal tissue at 10 µg

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 47 kDa
    Observed band size: 44 kDa
    why is the actual band size different from the predicted?


    Exposure time: 1 minute


    This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab209018 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

  • IHC image of ASS1 staining in a section of formalin-fixed paraffin-embedded normal human liver tissue*, performed on a Leica BONDTM. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20mins.  The section was then incubated with ab209018, 1/50 dilution, for 15 mins at room temperature. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. The inset negative control image is taken from an identical assay without primary antibody.

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

    *Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre

References

ab209018 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab209018.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up